The story was tied in with advice sent out by the Medicines and Healthcare products Regulatory Agency (MHRA) to healthcare professionals about how to report cases of suspected e-cigarette or vaping product associated lung injuries (EVALI). There will now be concerns about how effective the reporting will be, given the Covid-19 emergency. Healthcare professionals currently have a lot to deal with, but EVALI notification is triggered by patients with a history of e-cigarette use presenting with respiratory symptoms.
UK concern followed reports of deaths across the Atlantic. While cigarette smoking is the leading preventable cause of death, killing 480,000 people in the US each year - that’s nearly one in five deaths - the US Centers for Disease Control and Prevention (CDC) says that, as of 18 February, there have been 68 deaths attributable to EVALI.
The US cases show links with vitamin E acetate or tetrahydrocannabinol (THC) contained in the vaped liquids. These links are not reported in the UK deaths, where THC is a controlled drug and vitamin E acetate, along with other vitamins, is not permitted in e-cigarettes covered by UK legislation.
Both the NHS and Public Health England (PHE) support the use of vaping over smoking. In 2015, PHE estimated vaping was 95 per cent less harmful than smoking, and research continues to investigate the benefits. The Government has an ambitious policy of being ‘smoke free’ – defined as 5 per cent or less of the adult population being smokers – by 2030. Current projections suggest it is likely to miss that target, so there may be a further public policy push for smokers to turn to vaping.
The jury is still out on the mechanism of vaping deaths – apart, that is, from the Texan killed when his e-cigarette exploded in his face
Nicotine-containing e-cigarettes and e-liquids have been regulated since the introduction of the Tobacco and Related Products Regulations in May 2016. The regulations:
Other tobacco-related legislation prohibits the sale of nicotine inhaling products to under-18s. This provision is aimed at sellers. Breaches can lead to fines, and persistent breaches to restrictions on sellers. There is an exception, important for pharmacy, where the nicotine inhaling product is a medicinal product or device and the supply does not breach the Human Medicines Regulations.
The legislation does have a gap. Tobacco and nicotine products that are out of the scope (such as disposable e-cigarettes that do not contain nicotine, and 0 per cent nicotine e-liquids) do not have to meet the requirements.
The Yellow Card Scheme now covers e-cigarette reporting, and includes the e-liquids used for vaping. There is a specific e-cigarette reporting tool for the electronic scheme. Yellow card reports can be made for products that do not contain tobacco.
The jury is still out on the mechanism of vaping deaths apart, that is, from the Texan killed when his e-cigarette exploded in his face and tore his carotid artery, causing a massive stroke. Further research may provide detailed answers, but it is bound to be affected if reporting drops because of Covid-19. The current level of regulation is not intrusive, but may not go far enough as it covers only tobacco products. Research will need to lead the way in establishing whether regulation should be extended to all e-cigarette products. Even then, policymakers will have a conflict of interest to navigate if it is considered that additional regulation makes smokers less likely to switch to vaping.